Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Hughes

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|May 25, 2017
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense OligonucleotidesMark J Graham, Richard G Lee, Teresa A Brandt, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 1, 2018
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialMarcia Waddington-Cruz, Elizabeth J Ackermann, Michael Polydefkis, et al.
The New England Journal of Medicine|February 18, 2026
An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1Nicholas E Johnson, Li-Jung Tai, Johanna I Hamel, et al.
NPJ Vaccines|November 28, 2022
Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccineEugenia Z Ong, Jia Xin Yee, Justin S G Ooi, et al.
NPJ Vaccines|December 13, 2022
A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccineJenny G Low, Ruklanthi de Alwis, Shiwei Chen, et al.
Science Translational Medicine|November 20, 2015
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerDavid Hong, Razelle Kurzrock, Youngsoo Kim, et al.
Journal of Neurology|December 20, 2019
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosisTeresa Coelho, Aaron Yarlas, Marcia Waddington-Cruz, et al.
Journal for Immunotherapy of Cancer|November 18, 2018
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J Reilley, Patricia McCoon, Carl Cook, et al.
JAMA|September 28, 2023
Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyTeresa Coelho, Wilson Marques, Noel R Dasgupta, et al.
The New England Journal of Medicine|July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|May 25, 2017
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense OligonucleotidesMark J Graham, Richard G Lee, Teresa A Brandt, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 1, 2018
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialMarcia Waddington-Cruz, Elizabeth J Ackermann, Michael Polydefkis, et al.
The New England Journal of Medicine|February 18, 2026
An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1Nicholas E Johnson, Li-Jung Tai, Johanna I Hamel, et al.
NPJ Vaccines|November 28, 2022
Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccineEugenia Z Ong, Jia Xin Yee, Justin S G Ooi, et al.
NPJ Vaccines|December 13, 2022
A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccineJenny G Low, Ruklanthi de Alwis, Shiwei Chen, et al.
Science Translational Medicine|November 20, 2015
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerDavid Hong, Razelle Kurzrock, Youngsoo Kim, et al.
Journal of Neurology|December 20, 2019
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosisTeresa Coelho, Aaron Yarlas, Marcia Waddington-Cruz, et al.
Journal for Immunotherapy of Cancer|November 18, 2018
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J Reilley, Patricia McCoon, Carl Cook, et al.
JAMA|September 28, 2023
Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyTeresa Coelho, Wilson Marques, Noel R Dasgupta, et al.
The New England Journal of Medicine|July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
Pageof 4